GAMMA Investing LLC Buys 350 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

GAMMA Investing LLC increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 67.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 867 shares of the biopharmaceutical company’s stock after acquiring an additional 350 shares during the quarter. GAMMA Investing LLC’s holdings in Halozyme Therapeutics were worth $50,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of HALO. Rise Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 1st quarter worth about $25,000. International Assets Investment Management LLC bought a new position in Halozyme Therapeutics in the second quarter worth approximately $33,000. Whittier Trust Co. acquired a new stake in Halozyme Therapeutics in the first quarter valued at approximately $27,000. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $49,000. Finally, Fidelis Capital Partners LLC acquired a new position in shares of Halozyme Therapeutics during the first quarter worth approximately $52,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the transaction, the chief financial officer now owns 15,480 shares in the company, valued at $834,836.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of the business’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total transaction of $269,650.00. Following the sale, the chief financial officer now owns 15,480 shares of the company’s stock, valued at $834,836.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the transaction, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at $40,063,244.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 104,881 shares of company stock worth $5,990,684 over the last ninety days. 2.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms recently issued reports on HALO. TD Cowen lifted their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $58.00 to $62.00 in a report on Monday, October 7th. HC Wainwright restated a “buy” rating and issued a $65.00 target price on shares of Halozyme Therapeutics in a report on Friday, October 4th. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, The Goldman Sachs Group increased their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $60.44.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $53.46 on Thursday. The stock has a 50 day moving average of $58.80 and a 200 day moving average of $51.04. The company has a market capitalization of $6.80 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 0.49 and a beta of 1.27. Halozyme Therapeutics, Inc. has a 12 month low of $32.83 and a 12 month high of $65.53. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.18. The firm had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The business’s revenue was up 4.7% compared to the same quarter last year. During the same period last year, the firm posted $0.68 EPS. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.